ALN-CIDEB Investigational CIDEB-silencing RNAi therapy licensed to Regeneron, in Phase 2 development for metabolic dysfunction-associated steatohepatitis within the liver disease portfolio.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-CIDEB.
Add it to your Products I use list and share why you use it.